DUBLIN--(BUSINESS WIRE)--The "Antiviral Drugs Market Size, Share & Trends Analysis Report by Drug Class, by Application (HIV, Hepatitis, Influenza), by Type (Branded, Generic), by Region, and Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.
The global antiviral drugs market size is expected to reach USD 46.9 billion by 2027. It is estimated to register a CAGR of -2.3% over the forecast period. An increasing geriatric population is considered to be the major factor anticipated to drive the demand for efficient treatment of human immunodeficiency virus (HIV) infections.
According to the Centers of Disease Control and Prevention (CDC), nearly half the people diagnosed with HIV in U.S. are aged 50 and older. The number of persons aged 80 years and above is estimated to triple, from 143 million in 2019 to 426 million in 2050. The increasing aging population worldwide will have a direct impact on the healthcare systems, who would have to meet the needs of the aging population. This, in turn, will drive the demand for antiviral drugs, which can be used to treat a range of viral infections.
The presence of pipeline antiviral products for HIV therapeutics is anticipated to drive the market over the forecast period. For instance, ViiV Healthcare is developing Cabotegravir/rilpivirine (long-acting injectable), which is currently under Phase III and are types of NNRTI/ INSTI drug class. In addition, GS-6207 (capsid inhibitor) and vesatolimod (TLR-7 agonist) are being developed by Gilead Sciences and are currently under Phase I trial for the treatment of HIV. Moreover, advancements in epidemiology and growing awareness of viral diseases are expected to result in a high demand for efficient treatment solutions.
Further key findings from the report suggest:
- Reverse transcriptase inhibitors held the largest share in 2019 and is estimated to be the fastest-growing segment over the forecast period as these inhibitors slow down or prevent viral replication
- DNA polymerase inhibitors was the second-largest segment in 2019 owing to its effectiveness in combating drug resistance
- Generic products are estimated to be the fastest-growing segment over the forecast period owing to increased adoption of generic drugs in developing countries
- Hepatitis dominated the application segment in 2019 owing to the availability of various antiviral products for its treatment
- HIV is estimated to be the fastest-growing segment over the forecast period due to its increasing prevalence and incidence rate
- North America dominated the global antiviral drugs market in 2019 owing to the presence of key players in the region and the availability of a well-established healthcare infrastructure.
Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Antiviral Drugs Market Variables, Trends & Scope
3.1. Market Lineage outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Pipeline Analysis
3.4. Market Dynamics
3.5. Antiviral Drugs: Market Analysis Tools
Chapter 4. Antiviral Drugs Market: Segment Analysis, By Drug Class, 2016 - 2027 (USD Billion)
4.1. Definitions & Scope
4.2. Drug class market share analysis, 2019 & 2027
4.3. Segment Dashboard
4.4. Global Antiviral Drugs Market, By Drugs Class, 2016 to 2027
4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
Chapter 5. Antiviral Drugs Market: Segment Analysis, By Type, 2016 - 2027 (USD Billion)
5.1. Definitions & Scope
5.2. Type market share analysis, 2019 & 2027
5.3. Segment Dashboard
5.4. Global Antiviral Drugs Market, By Type, 2016 to 2027
5.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
Chapter 6. Antiviral Drugs Market: Segment Analysis, By Application, 2016 - 2027 (USD Billion)
6.1. Definitions & Scope
6.2. Application market share analysis, 2019 & 2027
6.3. Segment Dashboard
6.4. Global Antiviral Drugs Market, By Application, 2016 to 2027
6.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
Chapter 7. Antiviral Drugs Market: Regional Market Analysis, By Region, 2016 - 2027 (USD Billion)
7.1. Definitions & Scope
7.2. Regional market share analysis, 2019 & 2027
7.3. Regional Market Dashboard
7.4. Regional Market Share and Leading Players, 2019
7.5. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
7.6. Market Size, & Forecasts and Trend Analysis, 2019 to 2027
Chapter 8. Antiviral drugs market - Competitive Analysis
8.1. Recent developments & impact analysis, by key market participants
8.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
8.3. Public Companies
8.4. Private Companies
8.5. Key companies profiled
- Gilead Sciences
- F. Hoffmann-La Roche AG
- GlaxoSmithKline plc.
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
- Bristol-Myers Squibb Company
- Cipla Inc.
- Aurobindo Pharma
- Dr. Reddy's Laboratories Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/yjs14w.
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.